avalglucosidase alfa


( Last Updated : September 2, 2021)
Generic Name:
avalglucosidase alfa
Project Status:
Pending
Therapeutic Area:
Pompe disease
Manufacturer:
Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
(TBC)
Project Line:
Reimbursement Review
Project Number:
SR0703-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
As per Health Canada submitted indication, for the long-term treatment of patients with Pompe disease and as per current access of the other ERT available for the treatment of Pompe Disease, Alglucosidase alfa (Myozyme).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Avalglucosidase alfa is an enzyme replacement therapy (ERT) indicated for the long-term treatment of patients with Pompe disease (acid α-glucosidase deficiency).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.